Anti-PD-1 monoclonal antibody

The phase 3 KEYNOTE-522 trial investigating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with chemotherapy has met one...


The European Commission ( EC ) has approved Keytruda , an anti-PD-1 therapy, as monotherapy or in combination with Platinum...


The FDA ( Food and Drug Administration ) has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, in combination with...


Updated preliminary clinical data from an ongoing phase I dose escalation and expansion study evaluating the safety and efficacy of...



The European Commission has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, in combination with Pemetrexed ( Alimta ) and...


The results from an interim analysis of KEYNOTE-057, a phase 2 trial evaluating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy,...


The pivotal phase 3 KEYNOTE-426 trial investigating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with Axitinib ( Inlyta...


The FDA ( U.S. Food and Drug Administration ) has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, in combination...


New immunotherapy treatments offer a remarkable chance for survival for patients with advanced melanoma and hard-to-treat cancers of the bladder,...


The FDA ( U.S. Food and Drug Administration ) has approved Keytruda ( Pembrolizumab ), the anti-PD-1 ( programmed death...


Updated results from the phase 3 KEYNOTE-045 trial evaluating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in patients with locally...


The Food and Drug Administration ( FDA ) has approved Keytruda ( Pembrolizumab), an anti-PD-1 ( programmed death receptor-1 )...



The Food and Drug Administration ( FDA ) has approved Keytruda ( Pembrolizumab ), the anti-PD-1 ( programmed death receptor-1...


The European Commission ( EC ) has approved Keytruda ( Pembrolizumab ), the anti-PD-1 therapy, at a dose of 2...


Merck, known as MSD outside the United States and Canada, has announced new study findings investigating the use of Keytruda...


Findings investigating the use of Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in multiple, difficult-to-treat cancers, including advanced small cell...


New data from KEYNOTE-001, a phase 1b study evaluating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in naïve and previously-treated...


Whereas vaccines are designed to stimulate tumor antigen-specific immune responses, immune checkpoint inhibitors, in theory, should remove the brakes on...